The antidote carbon monoxide
(57) Abstract:The invention relates to medicine and for the production of the antidote. The proposal is that, as an antidote carbon monoxide used bis-(1-vinylimidazole)-(Aziza). 5 table. The invention relates to a new medicinal and preventive tool, namely, the antidote carbon monoxide (carbon monoxide) azizoglu drug in the form of 1 ml of 6% aqueous solution of alzola 0.5% aqueous solution of novocaine.This tool can be used for protection of armed forces personnel and population from poisoning lethal doses of carbon monoxide emitted during fires, the action of some types of modern weapons and in extreme situations in the chemical, petrochemical, metallurgical and mining and other industries.As an antidote for acute carbon monoxide poisoning azizol has no analogues on the activity and structure among the famous antihypoxic drug. Currently, the most effective for carbon monoxide poisoning are hyperparasitaemia and exchange transfusion. Drugs used in medicine for the new connection (alzola) and tested as antidote carbon monoxide. Primary research is that of the properties showed that the priming carbon monoxide at a concentration of 1.2% on white mice weighing 18-22 g dose of 30-60 mg/kg connection ensures the survival of animals 62,5%
Preliminary results was a prerequisite for further in-depth study of the drug.The aim of the invention is the creation of medicinal and prophylactic treatments for poisoning lethal doses of carbon monoxide.This objective is achieved in that azizol at a dose of 60 mg (1 ml of 6% solution in 0.5% aqueous solution of novocaine) is well tolerated and necessary efficiency in carbon monoxide poisoning.The essence of the proposed invention is that a new drug, azizol at a dose of 60 mg (1 ml of 6% solution in 0.5% aqueous solution of novocaine) has the necessary antidote for action effectiveness criteria changes the characteristics of oxyhemoglobin. The drug does not cause changes in the functional state of the human body according to objective clinical observations of changes in blood pressure and heart rate, functional sedenii with the original data and the control group.In accordance with the order of Ministry of health of the USSR, No. 157 since 1986 and the decision of the Pharmacological Committee of the USSR Ministry of health (Protocol No. 3 from 10.06.86) specialists of the Military medical Academy. S. M. Kirov (Department of military field therapy) and the research Institute of Military medicine of the USSR conducted clinical trials on the tolerability and efficacy of the drug arizol. The investigated drug in the dosage form for injection 6% solution in 0.5% aqueous solution of novocaine, ampoules of 1 ml, and diluted solutions of the drug in concentrations of 2.4% participated In the trials of 24 healthy men aged 18-40 years. The subjects were hospitalized groups of 6 people each. The tests were carried out in two stages with the aim of:
1) the dosage of the drug according to the criteria of portability;
2) evaluation of the tolerability and efficacy of selected dose of the drug "blind" using placebo (calcium gluconate). The following examples illustrate the subject matter.P R I m e R 1. The manufacture of dosage forms alzola. Legform drug arizol, the substance is synthesized in Iriah SB as USSR on author. St. N 125532, 1978, made by the technology of sterile filtration and asepticsure 0.5% aqueous solution of novocaine. Before filtering the water-procaine solution of the preparation process for 5-10 min Aerosil for removing small opalescence and filtered through a filter paper under technical vacuum on a Buechner funnel. The prepared solution is colorless and transparent according to the project VFS on lectora of arizola. Sterilizing filtration of the solution alzola put through a filter Millipore" (diameter of pores 0,22 MK), mounted in a special coil connected to the installation of filtration under pressure of purified nitrogen. After careful filtering (solution 4 times filtered) system hose with filter cut off from the flask with the solution and attach it to the sterile burette for bottling. The filling of the drug is carried out in a sterile and carefully conducted purity ampoules of 3 ml, which is then sealed. Ampoules with lekforma next view on the content of mechanical impurities and burns on the control table GF-42 with the aim of rejection. Certification legform of alzola in accordance with VFS performed by the technical control Department of the Kiev chemical-Pharma - citiescape plant them. M. C. University. Storage dosage form of the drug at 20-23aboutWith showed that within 2 years what Tracia 2 and 4% was prepared directly before introduction, mixing 6% alzola with sterile 0.5% aqueous solution of novocaine.P R I m m e R 2. Research on the effectiveness of drug arizol. Studied solutions alzola in concentrations of 2,4,6% 0.5% aqueous solution of novocaine. The necessary antidote for the actions of efficiency has a dose of 60 mg alzola in the form of a 6% solution in 0.5% aqueous solution of novocaine volume of 1 ml In this regard, further studies performed using the specified dose and drug concentrations. Research on the effectiveness of alzola as antidote carbon monoxide conducted a study of the oxygen binding function of hemoglobin with the construction of the dissociation curve of oxyhemoglobin (BWW), by definition of P50and constants hill.The evaluation of the effectiveness of the drug arizol found that its introduction in the dose and dosage form causes a distinct decrease value, i.e. cooperativity subunits of hemoglobin, which should reduce the effect of Holden, and consequently, to increase tolerance of high concentrations of carboxyhemoglobin.P R I m e R 3. Study of tolerability of the drug arizol.It is established that doses of alzola 15 mg (2% solution), 3 is reavley common side effects of the drug. As the necessary antidote action efficiency has a dose of 60 mg alzola in the form of a 6% solution in 0.5% aqueous solution of novocaine volume of 1 ml, and further studies performed using the specified dose and drug concentrations. According to clinical observations of changes in blood pressure and heart rate, functional cardiovascular samples Rufe, and ECG results revealed no changes as compared to background characteristics within groups and between groups in terms of average values. Objective clinical data, biochemical and physiological studies are presented in table.2-5.Thus, the results of the test drug arizol performed in the inpatient clinical study involving healthy volunteers allow us to draw the following conclusions:
1. A single intramuscular injection of the drug arizol at a dose of 60 mg in 1 ml of 6% solution in 0.5% aqueous solution of novocaine practically does not cause changes in the functional state of healthy volunteers assessed by clinical, laboratory and physiological parameters, in comparison with the original dantogo action effectiveness criteria changes the characteristics of oxyhemoglobin and recommended farmkomiteta the USSR Ministry of health for use in medical practice. The use of bis-(1-vinylimidazole)-alzola as antidote carbon monoxide.
FIELD: organic chemistry, medicine, dermatology.
SUBSTANCE: invention relates to zinc and aliphatic halogen-carboxylic acid salts that can be used in treatment of benign neoplasms of skin and visible mucosa tissues. Invention proposes the following formula of zinc and aliphatic halogen-carboxylic acid salts: (1): wherein R means -CHal3, -CHHal2, -CH2Hal and (2): wherein R' means Alk, hydrogen atom (H); R'' means Hal; R' means Alk; R'' means H, Alk wherein in these formulae halogen atom can be represented by fluorine atom (F), chlorine atom (Cl), bromine atom (Br) or iodine atom (J). Invention provides the development of original preparation used in treatment of benign neoplasms of skin and visible mucosa tissues with low toxicity, rapid effect, expressed therapeutic effect and eliciting good tolerance, absence of complications in treatment, healing without formation of scar tissue. The development of the preparation provides expanding assortment of agents used in treatment of such diseases.
EFFECT: enhanced and valuable properties of agents.
FIELD: veterinary science.
SUBSTANCE: the present innovation deals with applying a multi-purpose complex preparation that contains the following components in 1 l of distilled water: sodium selenite 1.0; vitamin E/in the form of combinal E/7500 mg; succinic acid 10.0; zinc sulfate 10.0 and pharmazine 50000 U. The preparation should be introduced as intramuscular injections 45, 30, 15 d before delivery and during the day of delivery: in cows per 10-15 ml, for pigs and sheep per 5 ml, for youngsters after the birth: in calves - 5 ml, in piglets and lambs per 1-2 ml, in hens per 0.5 ml once/2 wk. The innovation is very efficient in increasing the quality and quantity of production, improving the growth and development in fetus and offspring, preventing some surgical and obstetric-gynecological pathologies.
EFFECT: higher efficiency of correction.
FIELD: veterinary science.
SUBSTANCE: invention relates to a composition used in prophylaxis and treatment of anemia in agricultural animals and poultry that comprises a mixture of chelates of iron, copper, zinc, cobalt, sodium, calcium with ethylenediamine-N,N'-disuccinic acid in the following ratio of components, wt.-%: copper chelates with ethylenediamine-N,N'-disuccinic acid, 0.45-0.60; zinc chelates with ethylenediamine-N,N'-disuccinic acid, 1.40-1.45; cobalt chelates with ethylenediamine-N,N'-disuccinic acid, 0.075-0.08; sodium chelates with ethylenediamine-N,N'-disuccinic acid 42.0-44.0; calcium chelates with ethylenediamine-N,N'-disuccinic acid, 12.0-13.0, and iron chelates with ethylenediamine-N,N'-disuccinic acid, the balance. Agent provides enhancing the blood hemoglobin content in animals by 28% as compared with animals receiving neither anti-anemic agents and by 12% as compared with animals receiving the preparation-analog.
EFFECT: enhanced effectiveness of composition.
4 tbl, 4 ex
SUBSTANCE: the present innovation deals with obtaining compositions being of bactericidal, antiphlogistic, regenerating, antioxidant and antimicrobial properties at no allergic action. Wound-healing preparation (variant 1) contains: stearic acid 4.5-6.0; purified lanolin and its derivatives 3.0-6.0; vegetable oil 3.0-5.0; Vaseline 1.5-2.5; glycerol 4.0-8.0; castor oil 8.0-12.0; zinc stearate 1.0-2.5; 70%- alcoholic extract of phytospecies 2.5-3.5; extract of common John's wort grass 3.5-8.5; dog rose oil or sea buckthorn oil 2.6-6.0; Na-salts of fatty acids of wool fat 0.3-0.6; triethanolamine 0.7-1.1; anesthesin 2.0-3.0; 10%-butyric solution of propolis 0.3-1.0; boric acid 0.4-0.6; purified water - the rest. Wound-healing preparation (variant 2) contains: stearic acid 4.5-6.0; purified lanolin and its derivatives 3.0-6.0; vegetable oil 3.0-5.0; Vaseline 1.5-2.5; glycerol 4.0-8.0; castor oil 8.0-12.0; zinc stearate 1.0-2.5; 70%-alcoholic extract of phytospecies 2.5-3.5; extract of common John's wort 3.5-8.5; dog rose oil or sea buckthorn oil 2.6-6.0; Na-salts of fatty acids of wool fat 0.3-0.6; triethanolamine 0.7-1.1; anesthesin 2.0-3.0; levomycetin or gentamycine 2.0-3.0; 10%-butyric solution of propolis 0.3-1.0; boric acid 0.4-0.6; purified water - the rest. Additional introduction of the extract of common John's wort has increased antioxidant properties; 10%-butyric propolis - antioxidant and bactericidal properties, and levomycetin and gentamycine - has widened the range of antimicrobial action. Application of the preparation suggested in patients with burns and wounds revealed positive therapeutic effect without any cicatricial neoplasms and allergic action. No contraindications had been established.
EFFECT: higher efficiency of application.
4 cl, 8 ex
SUBSTANCE: invention relates to application of Acizol, namely bis(1-vinylimidazole) zinc diacetate as coronary active anti-ischemia and anti-arrhythmia agent. Acizol makes it possible to limit development of necrosis zone in acute myocardium ischemia, to reduce frequency of complications and fatal cases, to normalize antrioventricular and intraventricular electrical conductivity , to prevent ciliary arrythmia.
EFFECT: improved anti-ischemia and anti-arrhythmia agent.
15 tbl, 7 dwg, 6 ex
SUBSTANCE: method involves administering Acizol (bis1-vinyl imidazole zinc diacetate).
EFFECT: stable remission; improved bone tissue resorption in postoperative period; accelerated periodontium tissue recovery.
3 dwg, 3 tbl
FIELD: chemical-pharmaceutical industry, metalloorganic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to polyacrylic acid incomplete zinc salt corresponding to the formula: (-CH2-CHCOOH-)n(-CH2CHCOOZn0.5-)m wherein n = 12000-35000; m = 1650-6650 wherein the content of zinc is (6-8 wt.-%) 0.0009-0.0012 g-at, the content of carboxyl groups is 0.0117-0.0122 g-equv/1 g of polymer, and molecular mass is in the limits 1000000-3000000 Da. Also, invention proposes a method for preparing this salt that involves addition of zinc acetate aqueous solution to polyacrylic acid solution, stirring the reaction mixture for 120-300 min and drying the prepared solution under vacuum at temperature 50°C, not above. Agent is prepared as a solution in the ratio 1-10 g of polyacrylic acid incomplete zinc salt in 100 ml of water. Agent shows antiseptic, hemostatic and wound-healing effect in its external using.
EFFECT: improved preparing method, valuable medicinal properties of agent.
3 cl, 1 tbl, 4 ex
SUBSTANCE: it is necessary to carry out complex medicinal therapy including specific antiviral preparations, group B-vitamins, immunocorrectors, injection of antiherpetic vaccine, and, also local therapy with derinate. Additionally, since the 1st d of exacerbation it is important to inject flosteron once i/m at 1.0 ml, cefotaxym i/m twice daily per 1.0 mg for 10 d. Immunomodulator halavit on the 1st d should be prescribed i/m at the dosage of 200 mg, and then for the next 15 d - twice daily per 100 mg i/m. Diazepam for 1 mo should be injected per 5.0 mg 4 times daily, and then per 2.5 mg 4 times daily for 1 mo, as well. One should daily inject atarax per 100 mg nocturnally for 1 mo and ketorol internally per 10 mg thrice daily for 10 d. Moreover, it is necessary to apply the composition out of 50.0 g zinc oxide, 5.0 ml ACD fraction and 25.0 g "Aciclovir" cream 4 times daily for 10 d. The innovation enables to considerably increase the efficiency of therapy due to improving the main immunological values, weakening local autoimmune reactions and, also, preventing the development of psychic disorders in such patients due to affecting viral neurotropic properties.
EFFECT: higher efficiency of therapy.
3 dwg, 1 ex
FIELD: medicine; dental surgery.
SUBSTANCE: for this purpose first of all root canals are filled with paste based on eugenol, zinc oxide, dry iodoform and lincomycin hydrochloride taken in ratio 3:3:1:1. Then cortical plate trepanation and cyst membrane extraction are followed with ultrasonic treatment of bone cavity through 0.05% miramistine within 5 minutes using ultrasonic device US-102 at exposure intensity 0.05-0.4 Wt/cm in pulse mode. Treated bone cavity is introduced with filling-bandage "Collost" and with mixed osteoplastic gel "Collost" and lincomycin hydrochloride taken in ratio 2:1, and is covered with membrane "Collost". Wound is isolated from mouth cavity with film "Dyplene-denta" with lincomycin.
EFFECT: enables to accelerated wound healing process due to complete osteointegration and angioosteogenesis of implanted material.
FIELD: medicine; pharmacology.
SUBSTANCE: composition for prevention and treatment of asthma and upper airways diseases is characterised by that it includes incense tree Boswellia serrata dry extract solution with Boswellia acids content in terms of β- Boswellia acid not less than 80%, in wheat germs oil mixed with pharmaceutically acceptable selenium source and encapsulated containing glycerine, gelatin, pharmaceutically acceptable zinc source and chicory dry extract. Composition production implies that pharmaceutically acceptable zinc source, chicory dry extract gelatin, glycerine are sequentially dissolved renovated water. Agitated mixture is used to make capsule thereafter filled with capsulation solution produced by stirring of wheat germs oil and pharmaceutically acceptable selenium source followed by gradual addition of incense tree Boswellia serrata dry extract, with Boswellia acids content in terms of β- Boswellia acid not less than 80% till it is completely dissolved. Produced capsules are kept at temperature 5-10°C and dried out.
EFFECT: produced composition has improved efficiency.
4 cl, 4 ex